What type of study is this?

This is a Literature Review study.

What question did this study set out to answer?

To resolve the paradox of EZH2 expression in triple-negative breast cancer by analyzing its impact on treatment outcomes.

March 8, 2026Open Access

View Full Paper

Ask AI

Bookmark

Authors

Analysis confirms dual outcomes of neoadjuvant chemotherapy on triple-negative breast cancer, suggesting PRC2 serves as a prognostic marker.

To resolve the paradox of EZH2 expression in triple-negative breast cancer by analyzing its impact on treatment outcomes.
Utilized GSE25066 dataset with 508 TNBC patients receiving neoadjuvant chemotherapy.
Examined relationships between EZH2 expression, pCR, and DRFS.
Applied Waddington attractor geometry for causal analysis.
High EZH2 expression correlates with better pCR and worse DRFS.
pCR was statistically significant (p<0.0001), while DRFS showed HR=1.363 (p=0.0047).
Identified optimal timing for EZH2 inhibitor intervention post-chemotherapy.

Eric Robert Lawson (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Analysis confirms dual outcomes of neoadjuvant chemotherapy on triple-negative breast cancer, suggesting PRC2 serves as a prognostic marker.